BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29287958)

  • 1. Fragment-based discovery of a potent NAMPT inhibitor.
    Korepanova A; Longenecker KL; Pratt SD; Panchal SC; Clark RF; Lake M; Gopalakrishnan SM; Raich D; Sun C; Petros AM
    Bioorg Med Chem Lett; 2018 Feb; 28(3):437-440. PubMed ID: 29287958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure-based comparison of two NAMPT inhibitors.
    Zhang SL; Xu TY; Yang ZL; Han S; Zhao Q; Miao CY
    Acta Pharmacol Sin; 2018 Feb; 39(2):294-301. PubMed ID: 28858298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure based design of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors from a phenotypic screen.
    Palacios DS; Meredith E; Kawanami T; Adams C; Chen X; Darsigny V; Geno E; Palermo M; Baird D; Boynton G; Busby SA; George EL; Guy C; Hewett J; Tierney L; Thigale S; Weihofen W; Wang L; White N; Yin M; Argikar UA
    Bioorg Med Chem Lett; 2018 Feb; 28(3):365-370. PubMed ID: 29275937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
    Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
    BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.
    Wang LF; Wang XN; Huang CC; Hu L; Xiao YF; Guan XH; Qian YS; Deng KY; Xin HB
    Lipids Health Dis; 2017 Apr; 16(1):82. PubMed ID: 28449683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
    Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
    J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
    Cea M; Cagnetta A; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Roccaro A; Sacco A; Calimeri T; Cottini F; Jakubikova J; Kong SY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
    Blood; 2012 Oct; 120(17):3519-29. PubMed ID: 22955917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.
    Clark DE; Waszkowycz B; Wong M; Lockey PM; Adalbert R; Gilley J; Clark J; Coleman MP
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2920-2926. PubMed ID: 27158141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.
    Zhang XQ; Lu JT; Jiang WX; Lu YB; Wu M; Wei EQ; Zhang WP; Tang C
    Neuroscience; 2015 Apr; 291():230-40. PubMed ID: 25684751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oleate ameliorates palmitate-induced reduction of NAMPT activity and NAD levels in primary human hepatocytes and hepatocarcinoma cells.
    Penke M; Schuster S; Gorski T; Gebhardt R; Kiess W; Garten A
    Lipids Health Dis; 2017 Oct; 16(1):191. PubMed ID: 28974242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicotinamide phosphoribosyl transferase regulates cell growth via the Sirt1/P53 signaling pathway and is a prognosis marker in colorectal cancer.
    Pan JH; Zhou H; Zhu SB; Huang JL; Zhao XX; Ding H; Qin L; Pan YL
    J Cell Physiol; 2019 Apr; 234(4):4385-4395. PubMed ID: 30191976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.
    Schuster S; Penke M; Gorski T; Gebhardt R; Weiss TS; Kiess W; Garten A
    Biochem Biophys Res Commun; 2015 Mar; 458(2):334-40. PubMed ID: 25656579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
    Ogino Y; Sato A; Uchiumi F; Tanuma SI
    Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
    Zheng X; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Wang Y; Yuen PW; Bair KW
    Bioorg Med Chem Lett; 2014 Jan; 24(1):337-43. PubMed ID: 24279990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.
    Barraud M; Garnier J; Loncle C; Gayet O; Lequeue C; Vasseur S; Bian B; Duconseil P; Gilabert M; Bigonnet M; Maignan A; Moutardier V; Garcia S; Turrini O; Delpero JR; Giovannini M; Grandval P; Gasmi M; Ouaissi M; Secq V; Poizat F; Guibert N; Iovanna J; Dusetti N
    Oncotarget; 2016 Aug; 7(33):53783-53796. PubMed ID: 27462772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Dragovich PS; Zhao G; Baumeister T; Bravo B; Giannetti AM; Ho YC; Hua R; Li G; Liang X; Ma X; O'Brien T; Oh A; Skelton NJ; Wang C; Wang W; Wang Y; Xiao Y; Yuen PW; Zak M; Zhao Q; Zheng X
    Bioorg Med Chem Lett; 2014 Feb; 24(3):954-62. PubMed ID: 24433859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.
    Grozio A; Sociali G; Sturla L; Caffa I; Soncini D; Salis A; Raffaelli N; De Flora A; Nencioni A; Bruzzone S
    J Biol Chem; 2013 Sep; 288(36):25938-25949. PubMed ID: 23880765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil.
    Bi TQ; Che XM; Liao XH; Zhang DJ; Long HL; Li HJ; Zhao W
    Oncol Rep; 2011 Nov; 26(5):1251-7. PubMed ID: 21743967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice.
    Nencioni A; da Silva RF; Fraga-Silva RA; Steffens S; Fabre M; Bauer I; Caffa I; Magnone M; Sociali G; Quercioli A; Pelli G; Lenglet S; Galan K; Burger F; Vázquez Calvo S; Bertolotto M; Bruzzone S; Ballestrero A; Patrone F; Dallegri F; Santos RA; Stergiopulos N; Mach F; Vuilleumier N; Montecucco F
    Thromb Haemost; 2014 Feb; 111(2):308-22. PubMed ID: 24196571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells.
    Ogino Y; Sato A; Kawano Y; Aoyama T; Uchiumi F; Tanuma SI
    Anticancer Res; 2019 Dec; 39(12):6457-6462. PubMed ID: 31810909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.